The 5-HT1A Receptor and Brain Development
5-HT1A 受体和大脑发育
基本信息
- 批准号:7445477
- 负责人:
- 金额:$ 1.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-18 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAlcoholismAlzheimer&aposs DiseaseAntibodiesAnxietyApoptoticAutoreceptorsBehaviorBindingBiological AssayBrainBrain DiseasesBromodeoxyuridineCREB1 geneCell Death InhibitionCell LineCell ProliferationCell divisionCellsCocaineCocaine AbuseCyclin-Dependent Kinase 4 Inhibitor BDNA NucleotidylexotransferaseDataDevelopmentDifferentiation AntigensDiseaseEmployee StrikesEndopeptidasesHippocampus (Brain)ImmunohistochemistryIn VitroIsoenzymesKnowledgeLabelLigandsLightLinkMeasurementMeasuresMediatingMental DepressionMitogen-Activated Protein KinasesMitoticMolecularMonitorMoodsMusNeuronal DifferentiationNeuronsNeurotransmitter ReceptorPathway interactionsPeptide HydrolasesPhosphorylationPlayPolymerase Chain ReactionPrincipal InvestigatorProliferating Cell Nuclear AntigenProsencephalonProtein Kinase C AlphaProteinsRegulationRelative (related person)RoleSchizophreniaSerotonin Receptor 5-HT1ASignal PathwaySignal TransductionSignal Transduction PathwaySliceSpecificityStagingStaining methodStainsSymptomsSynapsesSynaptic PotentialsSynaptophysinTestingThreonineTimeWestern Blottingage relatedcaspase-3daydesignemotion regulationin vitro Assayneurogenesisneuronal survivalneuroprotectionnovelnovel therapeuticspostnatalreceptorsynaptogenesis
项目摘要
DESCRIPTION (provided by applicant): The efficacy of the serotonin 1A receptor (5-HT1A-R)-specific ligands in treating depression, anxiety, and many related symptoms has prompted studies into the physiological significance and signaling mechanisms of this neurotransmitter receptor. Such studies have shown that the absence of this receptor in the forebrain, specifically during early postnatal development of mice, results in elevated anxiety levels. Studies in the applicant's laboratory have shown that stimulation of this receptor in a hippocampal neuron-derived cell line causes protection of these cells against apoptosis. The mechanism responsible for this protection involves stimulation of the mitogen activated protein kinase (MAPK) pathway, which in turn signals through protein kinase C alpha (PKCc0 to cause inhibition of the proapoptotic protein caspase-3. Since the normal emotional state is a product of appropriate neuronal connections among the various regions of the fore brain, such as hippocampus, amygdala, and prefrontal cortex, preceding observations suggest that the 5-HT1A-R plays an important role in division and maturation of neurons in these brain regions. The current proposal will test this hypothesis by using both cultured hippocampal slices as well as 5-HT1A-R (+/+) and 5-HT1A-R (-/-) mice. Cultured hippocampal slices from mice at post-natal days 5, 10, 15, and 20 will be treated with the 5- HT1A agonist 8-hydroxy-2 (di-n-propylamino) tetralin (8-OH-DPAT) and immunohistochemical techniques used to study stimulation of key proteins, like PKC(x, MAPK and CREB, that promote neuronal division as well as maturation and survival. An important objective of performing such signaling studies will be to elucidate the profile of age-dependent regulation of 5-HT1A-R signaling and its effect on division (measured by BrdU incorporation) and maturation (measured by MAP-2 and synaptophysin staining) of neuronal cells. Regulation of apoptosis will be tested by using an anti-active caspase-3 antibody (to record activation of caspase-3) and deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) (to monitor apoptosis-associated DNA fragmentation). In parallel, the activation of MAPK, CREB, PKCcq and downstream transcription factors that relay the MAPK signals (like Elk-l), as well as the inhibition of caspase-3 will be measured by Western blot analysis using lysates of the hippocampal slices. RNA prepared from the treated slices will be reverse transcribed to prepare cDNA probes for microarray analysis to test for the regulation of gene expression, especially of the cytoskeleton-associated protein Arc and the immediate early proteins like Fos and Jun. Similar studies will be carried out by injecting 8-OH-DPAT into 5-HT1A-R (+/+) and 5-HT1A-R (-/-) mouse pups (d5, dl0, d15, d20) and preparing cryosections of brains to monitor activation of MAPK, CREB, PKCcq and also the effect of such 5-HT1A-R signaling on division and maturation of neuronal cells in the hippocampus and associated areas. Results obtained from 5-HT1A-R (+/+) and 5-HT_A-R (-/-) mouse pups will help delineate the specific effects of 5-HTtA-R signaling and shed new light on the mechanistic role of the 5-HT1A-R in brain development.
描述(由申请人提供):5-HT1A受体(5-HT1A-R)特异性配体在治疗抑郁、焦虑和许多相关症状方面的有效性促使人们对这种神经递质受体的生理意义和信号机制进行研究。这类研究表明,前脑中缺乏这种受体,特别是在小鼠出生后的早期发育过程中,会导致焦虑水平上升。申请人实验室的研究表明,刺激海马神经元来源的细胞系中的这种受体可以保护这些细胞免受凋亡的影响。这种保护的机制涉及刺激丝裂原激活的蛋白激酶(MAPK)途径,进而通过蛋白激酶Cα(PKCc0)发出信号,导致促凋亡蛋白caspase-3的抑制。由于正常的情绪状态是前脑不同区域(如海马体、杏仁核和前额叶皮质)之间适当的神经元连接的产物,先前的观察表明5-HT1A-R在这些脑区神经元的分裂和成熟过程中发挥着重要作用。目前的建议将通过使用培养的海马片以及5-HT1A-R(+/+)和5-HT1A-R(-/-)小鼠来验证这一假设。来自出生后5、10、15和20天的小鼠的海马片将被5-HT1A激动剂8-羟基-2(二正丙氨基)四氢萘(8-OH-DPAT)和免疫组织化学技术处理,用于研究对关键蛋白的刺激,如PKC(x,MAPK和CREB),促进神经元分裂以及成熟和存活。进行这类信号研究的一个重要目标将是阐明5-HT1A-R信号的年龄依赖性调节及其对神经细胞分裂(通过BrdU掺入)和成熟(通过MAP-2和突触素染色)的影响。通过使用抗caspase-3抗体(用于记录caspase-3的激活)和脱氧核苷酸转移酶介导的dUTP缺口末端标记(TUNEL)(用于监测与凋亡相关的DNA片断)来测试对细胞凋亡的调节。同时,MAPK、CREB、PKCcq和传递MAPK信号的下游转录因子(如ELK-L)的激活以及对Caspase-3的抑制将通过使用海马片的裂解物进行Western印迹分析来测量。从处理过的切片中制备的RNA将被逆转录成cDNA探针,用于微阵列分析,以测试基因表达的调控,特别是细胞骨架相关蛋白Arc和即刻早期蛋白质如Fos和Jun.类似的研究将通过向5-HT1A-R(+/+)和5-HT1A-R(-/-)小鼠(d5,d0,d15,d20)注射8-OH-DPAT和制备大脑冰冻切片来监测MAPK,CREB,PKCcq的激活,以及这些5-HT1A-R信号对海马区和相关区域神经细胞分裂和成熟的影响。从5-HT1A-R(+/+)和5-HTA-R(-/-)小鼠身上获得的结果将有助于描述5-HTTA-R信号的具体作用,并为5-HT1A-R在脑发育中的机制作用提供新的线索。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PROBAL BANERJEE其他文献
PROBAL BANERJEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PROBAL BANERJEE', 18)}}的其他基金
A Chemical Strategy of Developing Resistance-Proof, Immune-Friendly Drugs
开发抗耐药性、免疫友好型药物的化学策略
- 批准号:
10113275 - 财政年份:2021
- 资助金额:
$ 1.08万 - 项目类别:
Phosphatidylserine Translocase and Calcium Channels
磷脂酰丝氨酸转位酶和钙通道
- 批准号:
6460322 - 财政年份:1998
- 资助金额:
$ 1.08万 - 项目类别:
REGULATION OF APOPTOSIS BY THE SEROTONIN 1A RECEPTOR
5-羟色胺 1A 受体对细胞凋亡的调节
- 批准号:
2612538 - 财政年份:1998
- 资助金额:
$ 1.08万 - 项目类别:
Phosphatidylserine Translocase and Calcium Channels
磷脂酰丝氨酸转位酶和钙通道
- 批准号:
6747822 - 财政年份:1998
- 资助金额:
$ 1.08万 - 项目类别:
Regulation of ATPase II and Clearance of Cancer Cells
ATPase II 的调节和癌细胞的清除
- 批准号:
6944110 - 财政年份:1998
- 资助金额:
$ 1.08万 - 项目类别:
Phosphatidylserine Translocase and Calcium Channels
磷脂酰丝氨酸转位酶和钙通道
- 批准号:
6561733 - 财政年份:1998
- 资助金额:
$ 1.08万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 1.08万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 1.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 1.08万 - 项目类别: